SB-649915, a novel, potent 5-HT sub(1A) and 5-HT sub(1B) autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue

An increase in brain 5-HT levels is thought to be the key mechanism of action which results in an antidepressant response. It has been proven that selective serotonin re-uptake inhibitors are effective antidepressants but the delay to therapeutic onset of these agents is thought to be due to the tim...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2006-01, Vol.536 (1-2), p.54-61
Hauptverfasser: Scott, Claire, Soffin, Ellen M, Hill, Matthew, Atkinson, Peter J, Langmead, Christopher J, Wren, Paul B, Faedo, Stefania, Gordon, Laurie J, Price, Gary W, Bromidge, Steve, Johnson, Christopher N, Hagan, James J, Watson, Jeannette
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An increase in brain 5-HT levels is thought to be the key mechanism of action which results in an antidepressant response. It has been proven that selective serotonin re-uptake inhibitors are effective antidepressants but the delay to therapeutic onset of these agents is thought to be due to the time required for 5-HT sub(1A), and possibly 5-HT sub(1B), autoreceptor desensitisation. Therefore an agent incorporating 5-HT re-uptake inhibition coupled with 5- HT sub(1A) and/or 5-HT sub(1B) autoreceptor antagonism may provide a fast acting clinical agent. The current studies describe the in vitro profile of SB-649915 (6-[(1-{2-[(2-methylquinolin-5-yl)oxy]ethyl}piperidin-4-yl)methyl] -2H-1 ,4- benzoxazin-3(4H)-one), a novel compound which has high affinity for human recombinant 5-HT sub(1A), 5-HT sub(1B) and 5-HT sub(1D) receptors (pK sub(i) values of 8.6, 8.0, 8.8, respectively) and the human recombinant 5-HT transporter (pK sub(i) value of 9.3). SB-649915 also displays high affinity for rat, guinea pig, mouse and marmoset native tissue 5-HT sub(1A), 5-HT sub(1B) and 5- HT sub(1D) receptors and rat native tissue 5-HT transporters (pK sub(i) values >= 7.5). In functional [ super(35)S]GTP gamma S binding studies, SB-649915 (up to 1 mu M) does not display intrinsic activity in HEK293 cells expressing human recombinant 5-HT sub(1A) receptors but acts as a partial agonist at human recombinant 5- HT sub(1B) and 5-HT sub(1D) receptors with intrinsic activity values of 0.3 and 0.7, respectively, as compared to the full agonist 5-HT. From Schild analysis, SB- 649915 caused a concentration-dependent, rightward shift of 5-HT-induced stimulation of basal [ super(35)S]GTP gamma S binding in cells expressing human recombinant 5-HT sub(1A) or 5-HT sub(1B) receptors to yield pA sub(2) values of 9.0 and 7.9, respectively. In electrophysiological studies in rat dorsal raphe nucleus, SB-649915 did not affect the cell firing rate up to 1 mu M but attenuated (+)8-hydroxy-2-(di-n-propylamino) tetralin-induced inhibition of cell firing with an apparent pK sub(b) value of 9.5. SB-649915 (1 mu M) significantly attenuated exogenous 5-HT-induced inhibition of electrically- stimulated [ super(3)H]5-HT release from guinea pig cortex. In studies designed to enhance endogenous 5-HT levels, and therefore increase tone at 5-HT sub(1B) autoreceptors, SB-649915 significantly potentiated [ super(3)H]5-HT release at 100 and 1000 nM. In LLCPK cells expressing human recombinant 5-HT transporters an
ISSN:0014-2999
DOI:10.1016/j.ejphar.2006.02.042